Guardant Health Current Ratio 2017-2022 | GH

Guardant Health current ratio from 2017 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Guardant Health Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $1.13B $0.18B 6.46
2022-06-30 $1.04B $0.17B 6.18
2022-03-31 $1.11B $0.23B 4.87
2021-12-31 $1.11B $0.20B 5.72
2021-09-30 $1.59B $0.10B 15.58
2021-06-30 $1.89B $0.10B 19.57
2021-03-31 $2.03B $0.10B 21.29
2020-12-31 $1.89B $0.07B 28.27
2020-09-30 $1.09B $0.07B 15.11
2020-06-30 $1.01B $0.07B 14.42
2020-03-31 $0.61B $0.08B 7.38
2019-12-31 $0.60B $0.07B 8.21
2019-09-30 $0.58B $0.07B 8.60
2019-06-30 $0.60B $0.06B 10.59
2019-03-31 $0.51B $0.05B 10.63
2018-12-31 $0.47B $0.05B 9.99
2018-09-30 $0.30B $0.03B 9.27
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2016-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.183B $0.374B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00